Abstract:Background: WHO issued the first edition catalogue of Mycobacterium tuberculosis complex (MTBC) mutations associated with drug resistance in 2021. However, country-specific issues might lead to arising complex and additional drug-resistant mutations. We aimed to fully reflect the characteristics of drug resistance mutations in China. Methods: We analysed MTBC isolates from the nationwide drug-resistant tuberculosis surveillance with 70 counties in 31 provinces, municipalities, and autonomous regions in China. Three types of MYCOTB plates were used to perform drug susceptibility testing for 12 antibiotics (rifampicin, isoniazid, ethambutol, levofloxacin, moxifloxacin, amikacin, kanamycin, ethionamide, clofazimine, linezolid, delamanid, and bedaquiline). Mutations were divided into five groups according to their odds ratios, positive predictive values, false discovery rate-corrected p values, and 95% CIs: (1) associated with resistance; (2) associated with resistance-interim; (3) uncertain significance; (4) not associated with resistance-interim; and (5) not associated with resistance. The Wilcoxon rank-sum and Kruskal-Wallis tests were used to quantify the association between mutations and minimum inhibitory concentrations (MICs). Our dataset was compared with the first edition of the WHO catalogue. Findings: We analysed 10 146 MTBC isolates, of which 9071 (89·4%) isolates were included in the final analysis. 744 (8·2%) isolates were resistant to rifampicin and 1339 (14·8%) to isoniazid. 208 (1·9%) of 11 065 mutations were classified as associated with resistance or associated with resistance-interim. 33 (97·1%) of 34 mutations in group 1 and 92 (52·9%) of 174 in group 2 also appeared in groups 1 or 2 of the WHO catalogue. Of 81 indel mutations in group 2, 15 (18·5%) were in the WHO catalogue. The newly discovered mutation gyrA_Ala288Asp was associated with levofloxacin resistance. MIC values for rifampicin, isoniazid, moxifloxacin, and levofloxacin corresponding to resistance mutations in group 1 were significantly different (p<0·0001), and 12 high-level resistance mutations were detected. 61 mutations in group 3 occurred as solo in at least five phenotypically susceptible isolates, but with MIC values moderately higher than other susceptible isolates. Among 945 phenotypically resistant but genotypically susceptible isolates, 433 (45·8%) were mutated for at least one efflux pump gene. Interpretation: Our analysis reflects the complexity of drug resistance mutations in China and suggests that indel mutations, efflux pump genes, protein structure, and MICs should be fully considered in the WHO catalogue, especially in countries with a high tuberculosis burden. Funding: National Key Research and Development Program of China and the Science and Technology Major Project of Tibetan Autonomous Region of China.

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Pnca Mutations Are Associated with Slower Sputum Conversion During Standard Treatment of Multidrug-Resistant Tuberculosis.

Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.

Comparative Utility of Genetic Determinants of Drug Resistance and Phenotypic Drug Susceptibility Profiling in Predicting Clinical Outcomes in Patients with Multidrug-Resistant Mycobacterium Tuberculosis

Drug Exposure and Susceptibility of Second-Line Drugs Correlate with Treatment Response in Patients with Multidrug-Resistant Tuberculosis: a Multicentre Prospective Cohort Study in China.

Genetic factors associated with acquired phenotypic drug resistance and its compensatory evolution during tuberculosis treatment

Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment

Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China

Emergence of Additional Drug Resistance During Treatment of Multidrug-Resistant Tuberculosis in China: a Prospective Cohort Study.

Genetic Characterisation of Drug-Resistant Mycobacterium Tuberculosis in Rural China: a Population-Based Study.

Molecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium Tuberculosis in A Tuberculosis Referral Hospital in China

Phenotypic and genotypic analysis of drug resistance in M . tuberculosis isolates in Gansu, China

Improved Treatment Outcome of Multidrug-Resistant Tuberculosis with the Use of a Rapid Molecular Test to Detect Drug Resistance in China.

Risk Factors For Poor Treatment Outcomes In Patients With Mdr-Tb And Xdr-Tb In China: Retrospective Multi-Center Investigation

Treatment Outcomes of Multidrug-Resistant Tuberculosis Patients in Zhejiang, China, 2009–2013

The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis

Phenotypic Drug Susceptibility Characterization and Clinical Outcomes of Tuberculosis Strains with A-probe Mutation by GeneXpert MTB/RIF.

Experiences in Anti-Tuberculosis Treatment in Patients with Multiple Previous Treatments and Its Impact on Drug Resistant Tuberculosis Epidemics.

Genomic Analysis Identifies Mutations Concerning Drug-Resistance and Beijing Genotype in Multidrug-Resistant Mycobacterium Tuberculosis Isolated from China

Characterization of isoniazid resistance and genetic mutations in isoniazid-resistant and rifampicin-susceptible Mycobacterium tuberculosis in China